Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials by Gettinger, Scott N., MD, Huber, Rudolf M., MD, Kim, Dong-Wan, XX, Bazhenova, Lyudmila, XX, Hansen, Karin Holmskov, XX, Tiseo, Marcello, XX, Langer, Corey J., XX, Paz-Ares Rodríguez, Luis G., XX, West, Howard L., XX, Reckamp, Karen L., XX, Weiss, Glen J., XX, Smit, Egbert F., XX, Hochmair, Maximilian J., XX, Kim, Sang-We, XX, Ahn, Myung-Ju, XX, Kim, Edward S., XX, Groen, Harry J.M., XX, Pye, Joanna, XX, Liu, Yuyin, XX, Zhang, Pingkuan, XX, Vranceanu, Florin, XX, Camidge, D. Ross, XX

Get full text

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC by Hondelink, L.M., XX, Jebbink, M., XX, von der Thüsen, J.H., XX, Cohen, Danielle, MD, PhD, Dubbink, H.J., XX, Paats, M., XX, Dingemans, A.C., XX, de Langen, A.J., XX, Boelens, M.C., XX, Smit, E.F., XX, Postmus, P.E., XX, van Wezel, T., XX, Monkhorst, K., XX

Get full text